CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 57 enrolled / 57 target
Drug / intervention
Cabozantinibdrug
Likely dose
Cabozantinib 60 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04205799
NCT04205799Phase 2CompletedMonitor (0.7/mo)Completion was 41mo ago
CompareCT.gov

A Phase II Study Assessing Safety and Efficacy of Cabozantinib for Advanced or Metastatic Cervical Carcinoma After Platinum Treatment Failure

Centre Francois Baclesse·interventional·Posted Dec 19, 2019·Updated Jun 29, 2026

In Brief

A Phase 2 clinical trial evaluating Cabozantinib for Advanced/Metastatic Cervical Cancer. Completed, enrolled 57 participants across 8 sites.

Signals

Enrolling slower than its timeline implies

Detailed Summary

Assess efficacy and safety of cabozantinib in monotherapy in advanced/metastatic cervical cancer (CC) after failure of platinum-based regimen treatment.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdvanced/Metastatic Cervical Cancer
CountriesFrance
Collaborators--

Timeline

Phase 2CompletedFinished
2020202120222023202420252026
First PostedDec 19, 2019
Enrollment StartJan 15, 2020
Primary CompletionJan 15, 2023
TodayJul 2, 2026
Enrollment to primary: 3 yearsPosted 6.5 years ago

Arms & Interventions

CABOZANTINIBexperimental

Cabozantinib will be administered at the daily dose of 60 mg given orally in a 4-week cycle. It will be continued without interruption until disease progression or discontinuation for any cause.

Drug: Cabozantinib

Interventions

Cabozantinibdrug

Cabozantinib will be administered at the daily dose of 60 mg given orally in a 4-week cycle. It will be continued without interruption until disease progression or discontinuation for any cause.